SYNTARA LIMITED - Announcements

Market Cap $27.46M Add to my watchlist

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Announcements

Filter Results

All Price Sensitive Only

SNT	Section 708A(5)(e) Notice		21/04/21	140.61KB	Share
SNT	Becoming a substantial holder		20/04/21	183.5KB	Share
SNT	Appendix 2A		20/04/21	192.06KB	Share
SNT	Sale of Russian Distribution Rights	PRICE SENSITIVE	14/04/21	144.32KB	Share
SNT	Investor Presentation Capital Raising and Growth Outlook	PRICE SENSITIVE	14/04/21	2.45MB	Share
SNT	Proposed issue of Securities - PXS		14/04/21	24.78KB	Share
SNT	Placement	PRICE SENSITIVE	14/04/21	146.13KB	Share
SNT	Trading Halt	PRICE SENSITIVE	13/04/21	218.32KB	Share
SNT	Investor Presentation		07/04/21	3.32MB	Share
SNT	Appendix 2A - Exercise of Employee Options		07/04/21	193.49KB	Share
SNT	Clinical Trial of Treatment to Prevent Wound and Burns Scars		31/03/21	128.74KB	Share
SNT	US Commercial Launch of Bronchitol		19/03/21	99.5KB	Share
SNT	First Patient Enrolled - Clinical Trial for Cancer Treatment	PRICE SENSITIVE	22/02/21	132.47KB	Share
SNT	Appendix 2A - Exercise of Employee Options		15/02/21	193.44KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	10/02/21	430.36KB	Share
SNT	Pharmaxis Exports CF Drug to US - US$3 Million Milestone	PRICE SENSITIVE	09/02/21	101.56KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	180.59KB	Share
SNT	Quarterly Activity Report - December 2020	PRICE SENSITIVE	29/01/21	488.55KB	Share
SNT	Pharmaxis Receives US$7m milestone from Chiesi	PRICE SENSITIVE	29/12/20	96.51KB	Share
SNT	Appendix 2A - exercise of employee options		17/12/20	193.48KB	Share
SNT	Pharmaxis to Present at Proactive CEO Investor Session		10/11/20	101.35KB	Share
SNT	Change in substantial holding		06/11/20	126.59KB	Share
SNT	Change of Director's Interest Notice		04/11/20	140.69KB	Share
SNT	Appendix 3G - Employee Options		04/11/20	239.76KB	Share
SNT	Results of Meeting		04/11/20	185.75KB	Share
SNT	CEO Presentation to AGM		04/11/20	1.71MB	Share
SNT	Chairman's Address to Shareholders		04/11/20	148.49KB	Share
SNT	Ceasing to be a substantial holder from Arix Bioscience		03/11/20	234.45KB	Share
SNT	MEDIA RELEASE BRONCHITOL FDA and MF Trial		02/11/20	125.15KB	Share
SNT	Investor Presentation		02/11/20	3.12MB	Share
SNT	Investor Teleconference		02/11/20	111.81KB	Share
SNT	Pharmaxis Prioritises Clinical Program on Myelofibrosis	PRICE SENSITIVE	02/11/20	136.14KB	Share
SNT	FDA Approves Bronchitol for US Market	PRICE SENSITIVE	02/11/20	133.59KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/20	181.37KB	Share
SNT	September Quarter 2020 Activity Report	PRICE SENSITIVE	30/10/20	364.14KB	Share
SNT	Change in substantial holding from Arix Bioscience		23/10/20	160.26KB	Share
SNT	Change in substantial holding		20/10/20	193.29KB	Share
SNT	Pharmaxis Receives $5m R&D Tax Incentive		14/10/20	100.74KB	Share
SNT	Corporate Governance Statement		02/10/20	194.81KB	Share
SNT	Appendix 4G		02/10/20	181.15KB	Share
SNT	Notice of Annual General Meeting/Proxy Form		02/10/20	1.43MB	Share
SNT	Annual Report to shareholders		02/10/20	906.68KB	Share
SNT	Appendix 2A - exercise of employee options		01/10/20	193.48KB	Share
SNT	Appendix 2A - Exercise of Employee Options		24/09/20	193.5KB	Share
SNT	Appendix 2A - Exercise of Employee Options		18/09/20	194.58KB	Share
SNT	Date of Virtual AGM and Closing Date for Director Nomination		16/09/20	708.37KB	Share
SNT	Boehringer Ingelheim discontinues development of BI 1467335	PRICE SENSITIVE	07/09/20	684.06KB	Share
SNT	Pharmaxis Awarded $1M Australian Government Grant	PRICE SENSITIVE	03/09/20	123.9KB	Share
SNT	Appendix 2A - Employee Option Exercise		25/08/20	194.52KB	Share
SNT	Appendix 2A - 2020 Employee Share Plan Grant		24/08/20	197.88KB	Share
SNT	Ceasing to be a substantial holder from AEF		24/08/20	251.39KB	Share
SNT	FDA Gives Green Light to Start Myelofibrosis Phase 2 Study	PRICE SENSITIVE	19/08/20	91.4KB	Share
SNT	Change in substantial holding from AEF		19/08/20	108.98KB	Share
SNT	Appendix 2A - Exercise of employee options		14/08/20	195.09KB	Share
SNT	Final Director's Interest Notice		14/08/20	111.29KB	Share
SNT	Resignation of Non Executive Director Edward Rayner		14/08/20	99.44KB	Share
SNT	Proposed Issue of Securities to Chief Executive Officer		13/08/20	159.76KB	Share
SNT	Appendix 3G - 2020 Grant of Performance Rights		13/08/20	239.82KB	Share
SNT	Change of Director's Interest Notice - G Phillips		13/08/20	143.82KB	Share
SNT	Lapse of 2019 Performance Rights and Expiry of Options		13/08/20	154.09KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	13/08/20	934.75KB	Share
SNT	US$7 million Bronchitol Launch Milestone Brought Forward	PRICE SENSITIVE	05/08/20	101.07KB	Share
SNT	Fourth Quarter Activity Report	PRICE SENSITIVE	31/07/20	385.4KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/20	173.02KB	Share
SNT	Pharmaxis Submits IND Application for Myelofibrosis		23/07/20	90.96KB	Share
SNT	FDA Grants Orphan Drug Status for PXS Anti Fibrotic Drug		14/07/20	144.14KB	Share
SNT	PHARMAXIS TO PRESENT AT MONSOON COMMUNICATIONS WEBINAR		02/06/20	96.1KB	Share
SNT	Appendix 2A - Exercise of Employee Options Number 2		18/05/20	214.52KB	Share
SNT	Appendix 2A - Exercise of Employee Options		18/05/20	214.56KB	Share
SNT	Bronchitol NDA Resubmission - FDA Decision Date 1 November		13/05/20	511.37KB	Share
SNT	Chiesi Files Resubmission for Bronchitol with FDA		05/05/20	106.46KB	Share
SNT	Initial Director's Interest Notice		04/05/20	207.87KB	Share
SNT	Pharmaxis Appoints Dr Neil Graham as Director		04/05/20	102.66KB	Share
SNT	Investor Presentation		01/05/20	987.78KB	Share
SNT	Pharmaxis CEO to Present at Virtual Health Conference		30/04/20	103.05KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/20	88.08KB	Share
SNT	Pharmaxis Quarterly Shareholder Update - March 2020	PRICE SENSITIVE	30/04/20	392.68KB	Share
SNT	PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020	PRICE SENSITIVE	28/04/20	145.17KB	Share
SNT	Appendix 2A - Exercise of Employee Options		06/04/20	113.17KB	Share
SNT	Appendix 2A - Exercise of Employee Options		12/03/20	99.37KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	13/02/20	251.24KB	Share
SNT	Appendix 2A		13/02/20	99.51KB	Share
SNT	Appendix 3G - Exercise of Employee Options		12/02/20	78.53KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	121.39KB	Share
SNT	Quarterly Shareholder Update - December 2019	PRICE SENSITIVE	31/01/20	372.47KB	Share
SNT	Ceasing to be a substantial holder		20/12/19	162.14KB	Share
SNT	Pharmaxis Business Plan Update	PRICE SENSITIVE	18/12/19	112.13KB	Share
SNT	Boehringer discontinues development of BI 1467335 for NASH	PRICE SENSITIVE	18/12/19	120.18KB	Share
SNT	Investor Conference Call		17/12/19	108.98KB	Share
SNT	Trading Halt	PRICE SENSITIVE	16/12/19	101.39KB	Share
SNT	Investor Presentation		25/11/19	963.76KB	Share
SNT	Change of Director's Interest Notice		21/11/19	70.45KB	Share
SNT	Appendix 3B - Issue of Employee Options		21/11/19	129.97KB	Share
SNT	Results of Meeting		21/11/19	227.66KB	Share
SNT	CEO Presentation to 2019 AGM		21/11/19	959.76KB	Share
SNT	Chairman's Address to Shareholders		21/11/19	95.4KB	Share
SNT	Appendix 3B - Grant of Employee Options		06/11/19	129.56KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	121.37KB	Share
SNT	Quarterly Shareholder Update - September 2019	PRICE SENSITIVE	31/10/19	370.87KB	Share
SNT	Pharmaxis Science Update - Anti-Fibrotic Pipeline		30/10/19	128.23KB	Share

SNT Section 708A(5)(e) Notice
21/04/21		140.61KB	Share
SNT Becoming a substantial holder
20/04/21		183.5KB	Share
SNT Appendix 2A
20/04/21		192.06KB	Share
SNT Sale of Russian Distribution Rights
14/04/21	PRICE SENSITIVE	144.32KB	Share
SNT Investor Presentation Capital Raising and Growth Outlook
14/04/21	PRICE SENSITIVE	2.45MB	Share
SNT Proposed issue of Securities - PXS
14/04/21		24.78KB	Share
SNT Placement
14/04/21	PRICE SENSITIVE	146.13KB	Share
SNT Trading Halt
13/04/21	PRICE SENSITIVE	218.32KB	Share
SNT Investor Presentation
07/04/21		3.32MB	Share
SNT Appendix 2A - Exercise of Employee Options
07/04/21		193.49KB	Share
SNT Clinical Trial of Treatment to Prevent Wound and Burns Scars
31/03/21		128.74KB	Share
SNT US Commercial Launch of Bronchitol
19/03/21		99.5KB	Share
SNT First Patient Enrolled - Clinical Trial for Cancer Treatment
22/02/21	PRICE SENSITIVE	132.47KB	Share
SNT Appendix 2A - Exercise of Employee Options
15/02/21		193.44KB	Share
SNT Half Yearly Report and Accounts
10/02/21	PRICE SENSITIVE	430.36KB	Share
SNT Pharmaxis Exports CF Drug to US - US$3 Million Milestone
09/02/21	PRICE SENSITIVE	101.56KB	Share
SNT Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	180.59KB	Share
SNT Quarterly Activity Report - December 2020
29/01/21	PRICE SENSITIVE	488.55KB	Share
SNT Pharmaxis Receives US$7m milestone from Chiesi
29/12/20	PRICE SENSITIVE	96.51KB	Share
SNT Appendix 2A - exercise of employee options
17/12/20		193.48KB	Share
SNT Pharmaxis to Present at Proactive CEO Investor Session
10/11/20		101.35KB	Share
SNT Change in substantial holding
06/11/20		126.59KB	Share
SNT Change of Director's Interest Notice
04/11/20		140.69KB	Share
SNT Appendix 3G - Employee Options
04/11/20		239.76KB	Share
SNT Results of Meeting
04/11/20		185.75KB	Share
SNT CEO Presentation to AGM
04/11/20		1.71MB	Share
SNT Chairman's Address to Shareholders
04/11/20		148.49KB	Share
SNT Ceasing to be a substantial holder from Arix Bioscience
03/11/20		234.45KB	Share
SNT MEDIA RELEASE BRONCHITOL FDA and MF Trial
02/11/20		125.15KB	Share
SNT Investor Presentation
02/11/20		3.12MB	Share
SNT Investor Teleconference
02/11/20		111.81KB	Share
SNT Pharmaxis Prioritises Clinical Program on Myelofibrosis
02/11/20	PRICE SENSITIVE	136.14KB	Share
SNT FDA Approves Bronchitol for US Market
02/11/20	PRICE SENSITIVE	133.59KB	Share
SNT Appendix 4C - quarterly
30/10/20	PRICE SENSITIVE	181.37KB	Share
SNT September Quarter 2020 Activity Report
30/10/20	PRICE SENSITIVE	364.14KB	Share
SNT Change in substantial holding from Arix Bioscience
23/10/20		160.26KB	Share
SNT Change in substantial holding
20/10/20		193.29KB	Share
SNT Pharmaxis Receives $5m R&D Tax Incentive
14/10/20		100.74KB	Share
SNT Corporate Governance Statement
02/10/20		194.81KB	Share
SNT Appendix 4G
02/10/20		181.15KB	Share
SNT Notice of Annual General Meeting/Proxy Form
02/10/20		1.43MB	Share
SNT Annual Report to shareholders
02/10/20		906.68KB	Share
SNT Appendix 2A - exercise of employee options
01/10/20		193.48KB	Share
SNT Appendix 2A - Exercise of Employee Options
24/09/20		193.5KB	Share
SNT Appendix 2A - Exercise of Employee Options
18/09/20		194.58KB	Share
SNT Date of Virtual AGM and Closing Date for Director Nomination
16/09/20		708.37KB	Share
SNT Boehringer Ingelheim discontinues development of BI 1467335
07/09/20	PRICE SENSITIVE	684.06KB	Share
SNT Pharmaxis Awarded $1M Australian Government Grant
03/09/20	PRICE SENSITIVE	123.9KB	Share
SNT Appendix 2A - Employee Option Exercise
25/08/20		194.52KB	Share
SNT Appendix 2A - 2020 Employee Share Plan Grant
24/08/20		197.88KB	Share
SNT Ceasing to be a substantial holder from AEF
24/08/20		251.39KB	Share
SNT FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
19/08/20	PRICE SENSITIVE	91.4KB	Share
SNT Change in substantial holding from AEF
19/08/20		108.98KB	Share
SNT Appendix 2A - Exercise of employee options
14/08/20		195.09KB	Share
SNT Final Director's Interest Notice
14/08/20		111.29KB	Share
SNT Resignation of Non Executive Director Edward Rayner
14/08/20		99.44KB	Share
SNT Proposed Issue of Securities to Chief Executive Officer
13/08/20		159.76KB	Share
SNT Appendix 3G - 2020 Grant of Performance Rights
13/08/20		239.82KB	Share
SNT Change of Director's Interest Notice - G Phillips
13/08/20		143.82KB	Share
SNT Lapse of 2019 Performance Rights and Expiry of Options
13/08/20		154.09KB	Share
SNT Preliminary Final Report
13/08/20	PRICE SENSITIVE	934.75KB	Share
SNT US$7 million Bronchitol Launch Milestone Brought Forward
05/08/20	PRICE SENSITIVE	101.07KB	Share
SNT Fourth Quarter Activity Report
31/07/20	PRICE SENSITIVE	385.4KB	Share
SNT Appendix 4C - quarterly
31/07/20	PRICE SENSITIVE	173.02KB	Share
SNT Pharmaxis Submits IND Application for Myelofibrosis
23/07/20		90.96KB	Share
SNT FDA Grants Orphan Drug Status for PXS Anti Fibrotic Drug
14/07/20		144.14KB	Share
SNT PHARMAXIS TO PRESENT AT MONSOON COMMUNICATIONS WEBINAR
02/06/20		96.1KB	Share
SNT Appendix 2A - Exercise of Employee Options Number 2
18/05/20		214.52KB	Share
SNT Appendix 2A - Exercise of Employee Options
18/05/20		214.56KB	Share
SNT Bronchitol NDA Resubmission - FDA Decision Date 1 November
13/05/20		511.37KB	Share
SNT Chiesi Files Resubmission for Bronchitol with FDA
05/05/20		106.46KB	Share
SNT Initial Director's Interest Notice
04/05/20		207.87KB	Share
SNT Pharmaxis Appoints Dr Neil Graham as Director
04/05/20		102.66KB	Share
SNT Investor Presentation
01/05/20		987.78KB	Share
SNT Pharmaxis CEO to Present at Virtual Health Conference
30/04/20		103.05KB	Share
SNT Appendix 4C - quarterly
30/04/20	PRICE SENSITIVE	88.08KB	Share
SNT Pharmaxis Quarterly Shareholder Update - March 2020
30/04/20	PRICE SENSITIVE	392.68KB	Share
SNT PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
28/04/20	PRICE SENSITIVE	145.17KB	Share
SNT Appendix 2A - Exercise of Employee Options
06/04/20		113.17KB	Share
SNT Appendix 2A - Exercise of Employee Options
12/03/20		99.37KB	Share
SNT Half Yearly Report and Accounts
13/02/20	PRICE SENSITIVE	251.24KB	Share
SNT Appendix 2A
13/02/20		99.51KB	Share
SNT Appendix 3G - Exercise of Employee Options
12/02/20		78.53KB	Share
SNT Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	121.39KB	Share
SNT Quarterly Shareholder Update - December 2019
31/01/20	PRICE SENSITIVE	372.47KB	Share
SNT Ceasing to be a substantial holder
20/12/19		162.14KB	Share
SNT Pharmaxis Business Plan Update
18/12/19	PRICE SENSITIVE	112.13KB	Share
SNT Boehringer discontinues development of BI 1467335 for NASH
18/12/19	PRICE SENSITIVE	120.18KB	Share
SNT Investor Conference Call
17/12/19		108.98KB	Share
SNT Trading Halt
16/12/19	PRICE SENSITIVE	101.39KB	Share
SNT Investor Presentation
25/11/19		963.76KB	Share
SNT Change of Director's Interest Notice
21/11/19		70.45KB	Share
SNT Appendix 3B - Issue of Employee Options
21/11/19		129.97KB	Share
SNT Results of Meeting
21/11/19		227.66KB	Share
SNT CEO Presentation to 2019 AGM
21/11/19		959.76KB	Share
SNT Chairman's Address to Shareholders
21/11/19		95.4KB	Share
SNT Appendix 3B - Grant of Employee Options
06/11/19		129.56KB	Share
SNT Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	121.37KB	Share
SNT Quarterly Shareholder Update - September 2019
31/10/19	PRICE SENSITIVE	370.87KB	Share
SNT Pharmaxis Science Update - Anti-Fibrotic Pipeline
30/10/19		128.23KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 2.4¢		Change -0.002(7.69%)		Mkt cap ! $27.46M

Open	High	Low	Value	Volume
2.5¢	2.6¢	2.3¢	$24.40K	1.024M

Buyers (Bids)

No.	Vol.	Price($)
3	165101	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	594163	3

View Market Depth

No.	Vol.	Price($)
4	226661	0.023
3	93000	0.022
5	793867	0.021
13	3917674	0.020
3	1026988	0.019

Price($)	Vol.	No.
0.024	181768	2
0.025	159960	3
0.027	250000	2
0.029	347870	2
0.030	358058	3

Last trade - 14.22pm 21/06/2024 (20 minute delay)


Last 2.3¢		Change -0.002 ( 11.5 %)
Open	High	Low	Volume
2.5¢	2.5¢	2.3¢	555357
Last updated 15.21pm 21/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories